HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clairol buy

This article was originally published in The Rose Sheet

Executive Summary

P&G acquisition of hair care business from Bristol-Myers Squibb cleared by UK Office of Fair Trading after antitrust regulation office extended its decision deadline several weeks. U.S. Justice Department has yet to approve proposed deal, which also faces reviews in several other foreign markets. Clairol purchase for $4.95 bil. was announced in May; P&G believes deal will generate annual savings of $200 mil. by 2004 (1"The Rose Sheet" May 28, pp. 3-4)

You may also be interested in...



Clairol $50 Mil. Marketing Boost Part Of P&G Blueprint For Growth

Procter & Gamble plans to increase marketing spending on Clairol by approximately $50 mil. within its first year of acquiring the hair care business to "restore competitive marketing," President and CEO A.G. Lafley said during a May 21 analyst meeting outlining plans for the purchase.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009526

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel